Other Idiopathic Generalized Epilepsies

The idiopathic generalized epilepsies (IGEs) represent a group of epilepsy syndromes characterized by generalized seizure types, generalized spike-wave or polyspike-wave discharges on EEG, normal neurological examination, normal neuroimaging, and a presumed genetic etiology. Beyond juvenile myoclonic epilepsy (covered separately), the ILAE 2022 classification recognizes three additional IGE syndromes: juvenile absence epilepsy (JAE), epilepsy with generalized tonic-clonic seizures alone (GTCA), and epilepsy with eyelid myoclonia (Jeavons syndrome). Additionally, individuals who have generalized seizures with generalized spike-wave activity (2.5–5.5 Hz) but do not meet criteria for any specific IGE syndrome are classified as having genetic generalized epilepsy (GGE). Understanding the distinctions between these syndromes is important because they differ in prognosis, treatment response, and likelihood of seizure remission.

ILAE 2022 Classification of IGE Syndromes

The ILAE 2022 position statement formally defines four IGE syndromes as a subgroup within the broader category of genetic generalized epilepsy (GGE):

Juvenile Absence Epilepsy (JAE)

Epidemiology and Clinical Features

JAE accounts for approximately 8–10% of IGE syndromes. It bridges the phenotypic spectrum between childhood absence epilepsy and juvenile myoclonic epilepsy:

• Onset: 9–13 years (later than CAE, overlapping with JME)
• Absence seizures: The predominant seizure type; less frequent than in CAE (typically not daily) but more frequent than the absences seen in JME; duration 4–30 seconds
• GTC seizures: Present in ~80% of JAE patients (higher than CAE); often the presenting symptom; may occur upon awakening
• Myoclonic jerks: Present in a minority (~15–20%); when prominent, the diagnosis shifts toward JME
• Normal neurological examination and cognition

EEG Features

• Generalized 3–5.5 Hz spike-wave discharges; regular and symmetric
• Discharges may be slightly faster (3.5–5 Hz) than in CAE (3 Hz)
• Polyspike-wave components may be seen, overlapping with JME patterns
• Hyperventilation provokes discharges less reliably than in CAE
• Photoparoxysmal response present in a subset
• Ictal absence EEG: 3–5.5 Hz generalized spike-wave, often with abrupt onset and termination

Treatment and Prognosis

• First-line: Valproate (most effective for all seizure types); ethosuximide (if only absences, no GTC); lamotrigine (useful for absences and GTC); levetiracetam (for GTC prevention)
• NOT self-limited: Unlike CAE, JAE persists into adulthood in most patients; lifelong treatment is usually necessary
• Prognosis: Good seizure control (70–85%) with appropriate ASMs; GTC seizures are the main source of morbidity
• Relapse: High recurrence rate (60–80%) with ASM withdrawal

Epilepsy With Generalized Tonic-Clonic Seizures Alone (GTCA)

Clinical Features

GTCA (formerly "epilepsy with generalized tonic-clonic seizures on awakening") is the IGE syndrome in which generalized tonic-clonic seizures are the sole seizure type, without clinically apparent myoclonic or absence seizures:

• Onset: 10–25 years; may present later than other IGE syndromes
• Seizure pattern: GTC seizures occurring preferentially on awakening or during relaxation after stress; less commonly during sleep
• Frequency: Typically infrequent (yearly or less) but may cluster with provocative factors (sleep deprivation, alcohol)
• No clinically apparent absences or myoclonic jerks: Key diagnostic criterion; however, subtle myoclonus or brief absences may be detected on prolonged EEG monitoring
• Normal examination and cognition

EEG Features

• Generalized 3–5.5 Hz spike-wave or polyspike-wave discharges
• Often normal: Interictal EEG may be normal in up to 50% of patients; a single routine EEG has low sensitivity
• Sleep-deprived EEG or prolonged monitoring increases diagnostic yield
• Ictal EEG: Generalized spikes with tonic phase followed by spike-wave during clonic phase

Treatment

• First-line: Valproate (most effective); levetiracetam; lamotrigine
• Alternative: Topiramate, zonisamide, perampanel
• Avoid: Carbamazepine, phenytoin, vigabatrin, gabapentin (may worsen or fail to control generalized seizures)
• Lifestyle: Sleep hygiene and alcohol avoidance are critical; triggers are similar to JME
• NOT self-limited: Lifelong treatment is generally required; relapse rate is high with ASM withdrawal

Epilepsy With Eyelid Myoclonia (Jeavons Syndrome)

Clinical Features

Epilepsy with eyelid myoclonia (EEM), also known as Jeavons syndrome, is a distinctive and underrecognized epilepsy syndrome with prominent eyelid involvement and extreme photosensitivity:

• Onset: Typically in childhood (2–14 years; peak 6–8 years), but the syndrome persists into adulthood
• Defining feature — eyelid myoclonia: Rapid (3–6 Hz), rhythmic jerking of the eyelids with upward eye deviation, occurring immediately upon eye closure; may or may not be accompanied by brief absence (impaired awareness)
• Eye closure sensitivity: Eyelid myoclonia is triggered by voluntary or involuntary eye closure, a feature nearly unique to this syndrome
• Photosensitivity: Prominent and persistent; photoparoxysmal response on EEG in nearly all patients; sunlight, fluorescent lighting, and screens are triggers
• Other seizure types: GTC seizures (in ~50%); myoclonic jerks; typical absence seizures
• Self-induced seizures: Some patients learn to induce eyelid myoclonia by intentional eye closure or hand waving in front of a light source; this "self-stimulating" behavior can be mistaken for a tic or behavioral problem

EEG Features

Treatment and Prognosis

• Drug resistant: Up to 40–50% of patients have inadequate seizure control despite multiple ASMs; eyelid myoclonia is the most difficult seizure type to control
• ASM options: Valproate (most effective); levetiracetam; lamotrigine (caution: may worsen eyelid myoclonia in some); ethosuximide (for absence component); clobazam as adjunct
• Avoid: Carbamazepine, phenytoin, vigabatrin (worsen seizures); gabapentin/pregabalin
• NOT self-limited: Eyelid myoclonia and photosensitivity persist throughout life; GTC seizures may decrease with age
• Photosensitivity management: Blue-tinted lenses (Z1 lenses) reduce photoparoxysmal response; consistent ambient lighting; screen brightness reduction; avoidance of flickering lights
• Classification note: The ILAE 2022 classification places EEM as a childhood-onset generalized epilepsy that may be associated with an epileptic encephalopathy in some patients (when cognitive impairment develops), distinguishing it from the other "benign" IGE syndromes

Absence Status Epilepticus in IGE

Absence status epilepticus (ASE) is an important and sometimes underrecognized complication in patients with IGE syndromes. It manifests as a prolonged confusional state with subtle or minimal motor manifestations:

• Clinical presentation: Sustained altered awareness ranging from mild confusion and psychomotor slowing to a near-stuporous state; patients may appear "spacey" or have difficulty following commands; subtle eyelid fluttering or perioral twitching may be the only motor signs
• Duration: May last hours to days if unrecognized; distinguished from single absence seizures by duration >30 minutes (though shorter episodes are sometimes considered)
• EEG: Continuous or near-continuous generalized spike-wave or polyspike-wave discharges (typically at 2.5–4 Hz); may be slightly slower than the patient's typical interictal discharges
• Triggers: ASM noncompliance (most common); inappropriate ASM changes (e.g., switching from broad-spectrum to sodium channel blocker); sleep deprivation; alcohol; menstruation
• Treatment: IV benzodiazepines (lorazepam, diazepam) are highly effective and produce rapid resolution; oral clobazam for mild cases; correct the precipitating factor (restart ASM, withdraw offending agent)
• Prognosis: Excellent with appropriate treatment; no lasting cognitive sequelae in most cases; recurrence prevention requires identification and correction of the trigger

Psychiatric Comorbidities in IGE

Psychiatric comorbidities are common across all IGE syndromes and significantly impact quality of life:

Genetic Generalized Epilepsy (GGE): The Broader Category

When a patient demonstrates generalized seizure types and EEG shows generalized spike-wave activity (2.5–5.5 Hz) but the clinical picture does not fit the specific criteria of any of the four IGE syndromes, the ILAE recommends classifying the patient as having genetic generalized epilepsy (GGE). This may occur when:

• The specific combination of seizure types is atypical for any defined IGE syndrome
• The age of onset falls outside the typical range for a specific IGE
• Clinical features overlap between two or more IGE syndromes without clearly favoring one
• The clinical information is insufficient for specific syndromic diagnosis

Treatment Principles for All IGE/GGE

Long-Term Outcomes and Transition of Care

Transition from Pediatric to Adult Care

Many IGE syndromes begin in childhood or adolescence, requiring a planned transition to adult epilepsy care:

• Knowledge transfer: Patients must understand their specific IGE syndrome, the rationale for lifelong treatment (in JAE, JME, GTCA), the importance of trigger avoidance, and medication adherence
• Reproductive counseling: Begin early, well before pregnancy planning; discuss teratogenic risks of valproate; establish a plan for preconception ASM optimization; ensure adequate folate supplementation
• Driving and employment: Ensure patients understand local driving regulations; seizure-free requirements vary by jurisdiction; employment restrictions may apply (e.g., commercial driving, operating heavy machinery, working at heights)
• Insurance and medication access: Address potential gaps in medication access during the transition from pediatric to adult insurance coverage; medication disruption is a common trigger for seizure recurrence
• Psychosocial support: Address the psychological impact of a lifelong condition; connect with epilepsy support organizations; screen for depression and anxiety

Aging with IGE

• Seizure frequency: Many patients experience improved seizure control with age; GTC seizure frequency tends to decrease after the fourth decade
• ASM considerations in older adults: Enzyme-inducing ASMs (if still prescribed) increase the risk of osteoporosis and cardiovascular disease; valproate-associated tremor may worsen with age; levetiracetam and lamotrigine are generally well tolerated in older adults
• Comorbidity management: Drug interactions between ASMs and medications for common age-related conditions (cardiovascular disease, diabetes, osteoporosis) require careful management
• Late-onset GGE: New-onset generalized epilepsy in older adults should NOT be assumed to be IGE; consider autoimmune encephalitis, late-onset focal epilepsy with secondary generalization, and neurodegenerative causes

References

1. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1475–1499.
2. Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age. Epilepsia 2022;63(6):1443–1474.
3. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood. Epilepsia 2022;63(6):1398–1442.
4. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
5. Mullen SA, Berkovic SF, Lowenstein DH, et al. Genetic generalized epilepsies. Epilepsia 2018;59(6):1148–1153.
6. Striano S, Capovilla G, Sofia V, et al. Eyelid myoclonia with absences (Jeavons syndrome): a well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions? Epilepsia 2009;50(Suppl 5):15–19.
7. Marini C, Scheffer IE, Nabbout R, et al. The genetics of the epilepsies. Curr Opin Neurol 2019;32(2):173–180.
8. Unterberger I, Trinka E, Kaplan PW, et al. Generalized nonmotor (absence) seizures — what do absence, generalized, and nonmotor mean? Epilepsia 2018;59(3):523–529.
9. Camfield CS, Camfield PR. Long-term outcome of juvenile absence epilepsy. Epilepsy Behav 2020;112:107382.
10. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55(8):1106–1109.
11. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522–530.
12. Vossler DG. First seizures, acute repetitive seizures, and status epilepticus. Continuum (Minneap Minn) 2025;31(1, Epilepsy):95–124.